Evidence map›Paper›PMID 39730175›Full record

ArticleCancer genomics & proteomics

Immune Stress-induced Tumor Mutation Burden and Neoantigen Expression in 4T1 Mammary Cancer Cells: A Potential Mechanism for Long-term Survival in Patients Treated With Immune Checkpoint Inhibitors.

Tomoyuki Ishiguro, Kazuyuki Takeda, Daisuke Takayanagi, Emiko Mura, Risako Suzuki, Toshiaki Tsurui, Nana Iriguchi, Yuya Hirasawa, Ryotaro Ohkuma, Masahiro Shimokawa and 8 more

Abstract read
In one paragraph

Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Tomoyuki IshiguroDepartment of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.
Kazuyuki TakedaLaboratory of Cell Biology, Biomedical Research Core Facilities, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Daisuke TakayanagiDepartment of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.
Emiko MuraDepartment of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.
Risako SuzukiDepartment of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.
Toshiaki TsuruiDepartment of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.
Nana IriguchiDepartment of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.
Yuya HirasawaDepartment of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.
Ryotaro OhkumaDepartment of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.
Masahiro ShimokawaDepartment of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.
Hirotsugu AriizumiDepartment of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.
Yutaro KubotaDepartment of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.
Atsushi HoriikeDepartment of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.
Masahiko IzumizakiDepartment of Physiology, School of Medicine, Showa University, Tokyo, Japan.
Satoshi WadaDepartment of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.
Kiyoshi YoshimuraDepartment of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.
Robert M HoffmanAntiCancer Inc., San Diego, CA, U.S.A.
Takuya TsunodaDepartment of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan; ttsunoda@med.showa-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe Kaplan-Meier curves for patients treated with immune checkpoint inhibitors (ICIs) display a small group of potentially-cured patients with long-term survival, creating a 'kangaroo-tail' shape of the survival curve. However, the mechanistic basis of this phenomenon and what occurs in patients whose cancer is resistant to ICIs remain unclear. The present study aimed to answer these questions. MATERIALS AND

methodsWe analyzed mutations in mouse 4T1 mammary-gland-derived cancer cells expressing the hemagglutinin antigen (4T1-HA), which were grown in either wild-type mice or cytotoxic T-lymphocyte (CTL)-loaded immunocompromised mice (RAG-/- + ACT) under immune stress. These mutations were compared to those in 4T1-HA cells grown in RAG-/- mice without immune stress as a control.

resultsThe number of gene mutations, the tumor mutation burden (TMB) and microsatellite instability (MSI) scores were increased in the cancer cells under immune stress. The mutations in the antigen protein were such that the protein retained its immunogenicity and could still function as a neoantigen. Repeated immune recognition of additional neoantigens may lead to the kangaroo-tail survival phenomenon. The common genetic mutations of the analyzed 4T1-HA cells under immune stress included genes related to immune response. Analysis of alternative splicing of genes showed that are accumulated gene alterations under immune stress related to cancer-cell proliferation. Copy-number variation (CNV) analysis indicated that normal-antigen presentation and immune responses may be impaired under immune stress.

conclusionCancer cells, under immune stress, may acquire both immune escape capabilities and increased immunogenicity. This dual effect could lead to either resistance or response to ICIs, respectively.

Indexed as

Antigens, NeoplasmImmune Checkpoint InhibitorsMutationAnimalsBreast NeoplasmsCell Line, TumorFemaleHumansMiceMice, Inbred BALB CStress, PhysiologicalAntigens, NeoplasmImmune Checkpoint Inhibitorscancer evolutionimmune checkpoint inhibitorimmune escapeImmune stressimmunotherapyneo-antigensomatic mutationstumor mutation burden

Identifiers

PMID39730175
PMCPMC11696327

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.